Martin Zweig Detailed Fundamental Analysis

Validea's guru fundamental report indicates that ELEVANCE HEALTH INC (ELV) scores 69% using the Martin Zweig Growth Investor model, which targets growth stocks with accelerating earnings and sales, reasonable valuations, and low debt. While ELV passed several individual criteria such as P/E ratio, current quarter earnings, and sales growth, it notably failed on metrics related to earnings growth over the past several quarters, earnings persistence, and long-term EPS growth, placing it below the 80% threshold typically signaling 'some interest' by the strategy.

Analysis

Validea's guru fundamental report indicates Elevance Health Inc. (ELV), a large-cap growth stock in the Insurance (Accident & Health) industry, scored 69% using the Martin Zweig Growth Investor model. This score falls below the 80% threshold typically indicating "some interest" by the strategy, which prioritizes growth stocks with persistent accelerating earnings and sales growth, reasonable valuations, and low debt. The overall sentiment surrounding this report is mixed, with a neutral tone and low market impact.

ELV demonstrated strength in several key areas, passing criteria such as its P/E ratio, current quarter earnings performance, and overall sales growth rate. The company also showed positive current quarter earnings growth and favorable insider transactions, suggesting some fundamental health and internal confidence. Its current quarter EPS growth also surpassed that of the prior three quarters.

However, the stock notably failed on critical growth persistence metrics, including earnings growth over the past several quarters, earnings persistence, and long-term EPS growth. Furthermore, its current quarter EPS growth did not exceed its historical growth rate, indicating a potential deceleration or inconsistency in its longer-term growth trajectory. These failures highlight a divergence from the consistent, accelerating growth profile sought by the Zweig model.

Key Decisions for Investors

• Investors should recognize that while Elevance Health (ELV) exhibits reasonable valuation and strong current quarter performance, its failure to meet long-term earnings persistence and accelerating growth criteria suggests it may not align with strategies focused on consistent, high-momentum growth.
• Prudent investors might consider ELV for its current fundamental strengths but should closely monitor future earnings reports for sustained acceleration and improved long-term EPS growth consistency.
• Given the neutral sentiment and low market impact, a wait-and-see approach or a deeper dive into the specific reasons for the long-term growth failures may be warranted before making significant position adjustments.